NICE issues osteoporosis guidance

The U.K.'s NICE issued final guidance on the use of drugs for both primary and secondary prevention of fractures in postmenopausal women with osteoporosis. NICE recommended the use of Fosamax alendronate from Merck (NYSE:MRK) for primary prevention of fractures in women 70 years or older and for women younger than 70 years old with certain risk factors. The agency also backed Fosamax for secondary prevention of fractures in women of all ages. Actonel risedronate or Didronel etidronate from Proctor & Gamble (NYSE:PG) were recommended as the first alternative treatment options in both primary and secondary prevention. ...